The epidemiology of acute respiratory failure in hospitalized patients: A Brazilian prospective cohort study  by Franca, Suelene Aires et al.
Journal of Critical Care (2011) 26, 330.e1–330.e8The epidemiology of acute respiratory failure in
hospitalized patients: A Brazilian prospective
cohort study☆
Suelene Aires Franca MD1, Carlos Toufen Junior MD⁎,1, André Luiz D. Hovnanian MD1,
André Luís P. Albuquerque MD1, Eduardo R. Borges MD1, Vladimir R.P. Pizzo MD1,
Carlos Roberto Ribeiro Carvalho MD1
Pulmonary Division, InCor, University of São Paulo Medical School, São Paulo, Brazil 05403-900a
d
A
C
in
V
B
0
dKeywords:
Intensive care unit;
Acute respiratory failure;
Risk factors;
Mortality;
Incidence;
Multivariable analysis;
Mechanical ventilationAbstract
Purpose: The purpose of this study was to assess risk factors associated with the development of acute
respiratory failure (ARF) and death in a general intensive care unit (ICU).
Materials and Methods: Adults who were hospitalized at 12 surgical and nonsurgical ICUs were
prospectively followed up. Multivariable analyses were realized to determine the risk factors for ARF
and point out the prognostic factors for mortality in these patients.
Results: A total of 1732 patients were evaluated, with an ARF prevalence of 57%. Of the 889
patients who were admitted without ARF, 141 (16%) developed this syndrome in the ICU. The
independent risk factors for developing ARF were 64 years of age or older, longer time between
hospital and ICU admission, unscheduled surgical or clinical reason for ICU admission, and severity
of illness. Of the 984 patients with ARF, 475 (48%) died during the ICU stay. Independent prognostic
factors for death were age older than 64 years, time between hospital and ICU admission of more
than 4 days, history of hematologic malignancy or AIDS, the development of ARF in ICU, acute lung
injury, and severity of illness.
Conclusions: Acute respiratory failure represents a large percentage of all ICU patients, and the high
mortality is related to some preventable factors such as the time to ICU admission.
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Acute respiratory failure (ARF) severe enough to
necessitate mechanical ventilation (MV) is the most common
organ failure in general intensive care units (ICUs). Despite
significant technological advances in mechanical ventilatory
support, the mortality is considerably high, exceeding 40%
in many series [1-3].
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outcomes of patients receiving MV for specific indications,
such as acute exacerbation of chronic obstructive pulmonary
disease [4,5], or the most severe form of ARF, acute lung
injury/acute respiratory distress syndrome (ALI/ARDS) [6-
9]. However, in a large Scandinavian study, the 90-day
mortality rate in patients with ARF was similar to that in
ALI/ARDS, namely, 41% and 42%, respectively [3]. Thus, it
is valuable to expand our scope to a broader population of
patients with ARF.
Information about the frequency and risk factors associ-
ated with ARF is of paramount relevance in the process of
developing new and preventive interventions to improve
clinical outcomes. Characterization of populations at higher
risk for in-hospital mortality also has important implications
in interpreting mortality statistics.
To address these questions, we undertook this prospective
study in a heterogeneous group of critically ill patients to (1)
determine the prevalence of ARF, (2) determine the
incidence of ARF in a population initially free of this
syndrome and identify the risk factors for ARF development,
and (3) determine the mortality rate of patients with ARF and
identify prognostic factors present at the time of ICU
admission that contribute independently to the mortality of
these patients.2. Methods
2.1. Study design, setting, and patients
We used a prospective cohort study which considered for
enrollment consecutive adult patients (≥18 years old) who
were hospitalized between December 1, 2000, and October
31, 2001, at 12 ICUs of Hospital das Clínicas, the principal
teaching hospital of University of Sao Paulo Medical School
and a major tertiary care referral center in Sao Paulo, Brazil.
Patients were ineligible if they died or were discharged
within 24 hours after ICU admission. Post-cardiac surgery
patients and patients primarily with cardiac disorders are
treated in separate dedicated units and were not included in
the study. Before data collection, the study protocol was
reviewed and approved by the institutional ethics committee.
Because of the anonymous and noninterventional profile of
this study, the need for informed consent was waived.
2.2. Data collection
Candidates for the study were prospectively identified by
a daily review of all admitted patients to each of the 12 ICUs
(a total of 87 beds). The following information was collected
for each eligible patient: ICU admission data relating to
demographic characteristics, previous health status, and a set
of clinical and laboratory parameters necessary to compute
the Simplified Acute Physiology Score II (SAPS II) [10] andthe Logistic Organ Dysfunction System (LODS) [11]. Acute
Physiology Score (APS) refers to the physiologic variables
that compound the SAPS II (excluding demographic and
clinical data). We calculated the APS points for each patient
and used them in place of SAPS II points in the analytic
phase of the study because we preferred to show the impact
of demographic and clinical characteristics by themselves on
the outcomes.
Daily evaluations to assess the occurrence of ARF were
performed during all the course of each ICU admission.
Acute respiratory failure was defined based on the need for
endotracheal intubation and mechanical ventilatory support
for at least 24 hours [1-3]. The main reason for the initiation
of MV was assigned, using prospectively defined criteria
from a list of categories suggested by Esteban et al [12].
Duration of MV was defined as the time elapsed from the
initiation of ventilatory support to extubation or death,
whichever came first.
Patients were separated into 2 groups according to the
presence or absence of ARF on admission to the ICU. Acute
respiratory failure present at ICU admission (“initial ARF”)
refers to the patients who developed necessity of MV within
the first 48 hours of ICU admission (including patients
already on mechanical ventilatory support at ICU admis-
sion); ARF developed after ICU admission (“late-onset
ARF”) refers to the patients who developed the necessity of
MV 48 hours or more after ICU admission. We have
determined the incidence and risk factors for the develop-
ment of ARF in patients without ARF at ICU admission and
the mortality and prognostic factors related to death during
the ICU stay for the total population of patients with ARF.
Patients were followed up until the end of their hospital stay.
All data were captured by the authors and recorded on a
standardized case report form developed for this study and
containing exact explanations and definitions of the
requested data. After the study period, the forms were
collected centrally and cleaned in detail by an intensive care
specialist medical physician for any missing information,
logical errors, insufficient detail, or addition of queries,
which were resolved by the one responsible for the collected
data. The data were manually entered into a computerized
database (Epi Info, version 6.04; Centers for Disease Control
and Prevention, Atlanta, Ga) for analysis.
2.3. Statistical analysis
Categorical variables were expressed in percentages
and 95% confidence intervals (95% CI); interval variables
were expressed as median and interquartile range (25th to
75th percentiles).
Bivariate analysis of predictor variables against outcome
variables (development of ARF in patients without ARF on
ICU admission, and death during the ICU stay for patients
with ARF) was performed. Nominal predictor variables were
transformed intomultiple dichotomous variables. Continuous
predictor variables (age, time between hospital and ICU
Table 1 Characteristics and outcomes of 1732 patients
admitted to an ICU during the study period, according to ARF
diagnosis a
Characteristic Total
patients
(n = 1 732)
Patients
with ARF
(n = 984)
Patients
without ARF
(n = 748)
Age, y 53 (39-69) 54 (38-70) 53 (40-67)
Female 43% (40-45) 39% (36-43) 47% (44-51)
Time between
hospital and ICU
admission, d
2 (0-7) 2 (0-7) 2 (0-7)
Type of admission
Medical 47% (45-49) 50% (47-54) 42% (39-46)
Scheduled surgical 34% (32-36) 27% (24-30) 44% (40-47)
Unscheduled
surgical
19% (17-21) 23% (20-26) 14% (11-16)
Comorbidities
Cancer 22% (21-25) 21% (18-23) 25% (22-28)
Metastatic cancer 5% (4-6) 5% (4-7) 5% (4-7)
Hematologic
cancer
4% (3-5) 4% (3-6) 3% (2-4)
AIDS 3% (2-4) 4% (3-5) 2% (1-3)
Trauma 11% (9-12) 14% (12-16) 6% (5-8)
SAPS II score 29 (18-41) 37 (27-48) 20 (13-29)
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were categorized using their tertile values, and all categories
were compared with the category having the lower mortality.
Subgroups were analyzed by a χ2 statistic or by a
nonparametric rank test (Mann-Whitney U test), for categor-
ical or interval predictor variables, respectively.
A multiple logistic regression analysis was used to
independently assess variables that in a bivariate analysis
were associated with development of or mortality from ARF;
those predictor variables associated with the outcome at P b
.20 were eligible for inclusion in the model. Because we have
a large sample size, with no missing data, we did not use a
variable selection procedure; rather we performed an “all
variable model.” With this model, all specified variables are
entered simultaneously, excluding the possibility of missing
suppresser effects or important changes in coefficients due to
exclusion of a modest confounder. Odds ratios (OR) were
estimated from the β coefficients obtained, and respective
95% CIs were calculated. P b .05 was considered to be
significant in all procedures. All statistical tests were 2-tailed.
Statistical analysis was performed with Epi Info, version
6.04 (Centers for Disease Control and Prevention), and
SPSS, version 10.0 for Windows (SPSS Inc, Chicago, Ill).APS score 14 (7-25) 21 (13-31) 7 (2-12)
LODS score 3 (1-5) 4 (2-6) 1 (0-3)
ICU LOS, d 5 (3-13) 9 (4-19) 3 (2-5)
Hospital LOS, d 18 (10-32) 21 (12-37) 15 (9-27)
ICU mortality 29% (27-31) 48% (45-51) 4% (2-5)
Hospital mortality 35% (33-38) 54% (51-57) 11% (9-13)
LOS indicates length of stay.
a Continuous data given as median (interquartile range); categorical
data given as percentage (95% CI).3. Results
Of the 2118 eligible patients admitted to ICUs during
the 11-month study period, 386 (18%) were not enrolled
because of limited resources. We had access only to the
administrative data set about these missed patients, but we
could check that there were no significant differences
between them and the 1732 enrolled patients in demo-
graphic characteristics (age [median, 52 vs 53 years], sex
[female, 45% vs 43%]) and medical outcomes (ICU length
of stay [median, 3 vs 6 days], hospital length of stay
[median, 12 vs 18 days], ICU mortality [24% vs 29%], and
hospital mortality [32% vs 35%]), all P N .05.
Of the 1732 enrolled patients, 843 (49%) were admitted to
an ICU with ARF. Of the 889 (51%) patients who were
admitted without ARF, 141 developed ARF during their stay
in the ICU, giving a total of 984 patients with ARF. The
overall ICU and hospital case fatality for the 1732 included
patients were 29% and 35%, respectively; that for the 984
patients with ARF were 48% and 54%, respectively; in
contrast, among the 748 patients who did not require MV,
only 27 (4%) died in the ICU and 81 (11%) died in the
hospital. The characteristics and outcomes of these 3 groups
of patients are shown in Table 1.
We compared the 141 patients with late-onset ARF with
the 748 patients without ARF to estimate the incidence rate
of and identify the risk factors for the development of ARF
during the intensive care period (risk factor cohort).
Adding these individuals with ARF (n = 141) to the
patients with ARF on admission (n = 843), we obtained a
cohort of 984 patients with ARF who were evaluated toestimate the overall mortality rate of and identify the
prognostic factors that contribute to death in this
population (prognostic factor cohort).
3.1. Incidence of and risk factors for ARF
As stated, of the 889 patients who were admitted to an
ICU without ARF, 141 (cumulative incidence, 16%; 95% CI,
14%-18%) developed ARF during their ICU stay. Patients
who developed ARF were older (median, 63 vs 53 years; P =
.005), more likely to be admitted to the ICU for medical
reasons (65% vs 42%; P = b .001), more frequently had a
history of hematologic malignancy (6% vs 3%; P = .04), and
had a greater severity of illness at ICU admission, as
evaluated by the SAPS II (median, 31 vs 20; P b .001), APS
(median, 15 vs 7; P b .001), and LODS (median, 3 vs 1; P b
.001) scores compared to patients who did not develop ARF
(Table 1). In clinical outcomes, these patients had a longer
ICU (median, 16 vs 3 days; P b .001) and hospital (median,
27 vs 15 days; P b .001) length of stay and an overall
mortality rate that was more than 7 times greater than that of
patients who did not develop ARF (hospital mortality, 80%
vs 11%; P b .001) (Table 1).
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while in the ICU, and the results of bivariate and multivariate
analyses are shown in Table 2. From the multivariate
analysis, independent risk factors for development of ARF
were 64 years of age or older, longer time between hospital
and ICU admission, ICU admission for unscheduled surgical
or medical reasons, and greater severity of illness at ICU
admission, as evaluated by the APS score.
3.2. Mortality and prognostic factors of mortality
in patients with ARF
As stated, of the 1732 enrolled patients, 843 were admitted
to an ICU with ARF and an additional 141 patients developed
ARF during their stay in the ICU, giving a total of 984 patients
with ARF (prevalence, 57%; 95% CI, 54%-59%). Among
these 984 patients with ARF, 475 died in the ICU (ICU
mortality rate, 48%; 95% CI, 45%-51%) and another 56 diedTable 2 Characteristics and outcomes of 889 patients (initially
free of ARF) admitted to an ICU during the study period,
according to ARF development status a
Characteristic Total
(n = 889)
Developed
ARF in ICU
(n = 141)
No ARF
(n = 748)
P
Age, y 54 (40-68) 63 (40-72) 53 (40-67) .005
Female 47% (44-51) 47% (38-55) 47% (44-51) .91
Delay between
hospital
and ICU
admission, d
2 (0-7) 2 (1-9) 2 (0-7) .09
Type of admission
Medical 46% (43-50) 65% (56-72) 42% (39-46) b.001
Scheduled
surgical
40% (36-43) 19% (13-27) 44% (40-47)
Unscheduled
surgical
14% (12-17) 16% (11-24) 14% (11-16)
Comorbidities
Cancer 24% (21-26) 16% (10-23) 25% (22-28) .02
Metastatic
cancer
5% (4-7) 5% (2-10) 5% (4-7) .90
Hematologic
cancer
3% (2-5) 6% (3-12) 3% (2-4) .04
AIDS 2% (1-4) 4% (2-9) 2% (1-3) .11
Trauma 6% (5-8) 6% (3-12) 6% (5-8) .96
SAPS II score 22 (14-31) 31 (26-41) 20 (13-29) b.001
APS score 7 (3-14) 15 (9-21) 7 (2-12) b.001
LODS score 1 (0-3) 3 (1-5) 1 (0-3) b.001
ICU LOS, d 4 (3-8) 16 (11-27) 3 (2-5) b.001
Hospital
LOS, d
16 (9-30) 27 (15-41) 15 (9-27) b.001
ICU mortality 15% (13-18) 77% (69-83) 4% (2-5) b.001
Hospital
mortality
22% (19-25) 80% (73-86) 11% (9-13) b.001
a Continuous data given as median (interquartile range); categorical
data given as percentage (95% CI).in the hospital after discharge from the ICU, resulting in the
overall hospital mortality of 54% (95% CI, 51%-57%).
Characteristics of the studied patients, the reasons for
instituting MV, and the outcomes are listed in Table 3.
Nonsurvivors of ARF were older (median, 62 vs 49 years;
P b .001), had a longer time between hospital and ICU
admission (median, 3 vs 1 days; P b .001), were more
likely to be admitted to the ICU for medical reasons (64%
vs 38%; P b .001), more frequently had a history of
hematologic malignancy (7% vs 1%; P b .001) or AIDS
(6% vs 2%; P = .001), and had a greater severity of illness
at ICU admission, as evaluated by the SAPS II (median,
44 vs 30; P b .001), APS (median, 26 vs 18; P b .001),
and LODS (median, 5 vs 3; P b .001) scores compared to
survivors of ARF. In clinical outcomes, survivors of ARF
had similar ICU (median, 8 vs 10 days; P = .183) and
longer hospital length of stay (median, 25 vs 17 days;
P b .001) than nonsurvivors of ARF (Table 4).
We studied the prognostic factors for death in patients
with ARF, and the results of bivariate and multivariate
analyses are shown in Table 5. From the multivariate
analysis, the independent prognostic factors for death in
these patients were older age (N64 years); time between
hospital and ICU admission of more than 4 days; history of
hematologic malignancy or AIDS; the development of ARF
at ICU (late-onset ARF), as opposed to ARF already present
on the moment of admission; initiation of MV because of
ALI/ARDS; and greater severity of illness at ICU admission,
as evaluated by an APS score higher than 26.4. Discussion
Acute respiratory failure is a common reason for ICU
admission worldwide. Five prospective multicenter cohort
studies evaluating patients requiring MV due to ARF of
different etiologies were published [1-3,13,14] and will be
compared with present study.
Acute respiratory failure was present in 49% of our
patients on ICU admission, with a further 8% of patients
developing ARF during their ICU stay. Thus, in this study,
a total of 57% of all ICU admissions for a length of more
than 24 hours had ARF at some point during their stay.
Such a high period prevalence is confirmed by 2 other
epidemiologic studies reporting that 56% of all ICU
admissions had ARF at some point during their stay [13]
and that ARF accounted for 69% of all ICU bed usage in
an urban European population [1]. It is unclear why
another large study of ARF yielded a much lower estimate
of 33% prevalence [14].
4.1. Incidence
Of the 889 patients who were admitted to an ICU without
ARF, 141 developed ARF later during the ICU stay,
representing a cumulative incidence of 16%. In the literature,
Table 3 Incidence of ARF by selected characteristics of 889 patients admitted to an ICU during the study period—bivariate and
multivariate analyses a
Characteristic Incidence of ARF,
% (95% CI)
Bivariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P
Age, y
b44 14% (11-19) 1.00 .143 1.00 .176
44-63 10% (7-15) 0.69 (0.42-1.13) .013 0.69 (0.40-1.18) .036
N63 22% (18-28) 1.70 (1.12-2.58) 1.66 (1.03-2.67)
Time between hospital and ICU admission, d
0 12% (8-16) 1.00 .059 1.00 .042
1-4 17% (14-22) 1.60 (0.98-2.60) .061 1.72 (1.02-2.90) .005
N4 17% (13-22) 1.61 (0.98-2.65) 2.22 (1.27-3.88)
Type of ICU admission
Scheduled surgical 8% (5-11) 1.00 .001 1.00 .006
Unscheduled surgical 18% (12-26) 2.70 (1.48-4.91) b.001 2.54 (1.30-4.94) b.001
Medical 22% (18-27) 3.44 (2.18-5.44) 2.77 (1.59-4.82)
Comorbidities
Cancer 10% (7-16) 0.56 (0.34-0.90) .017 0.89 (0.51-1.56) .691
Hematologic cancer 30% (15-49) 2.36 (1.06-5.27) .036 1.36 (0.56-3.27) .494
AIDS 30% (12-54) 2.33 (0.88-6.17) .089 2.32 (0.79-6.86) .127
APS score
b5 6% (4-10) 1.00 .030 1.00 .311
5-11 11% (8-16) 1.93 (1.06-3.50) b.001 1.40 (0.73-2.68) .001
N11 30% (25-36) 6.49 (3.79-11.10) 3.54 (1.72-7.28)
LODS score
0 7% (4-10) 1.00 .007 1.00 .488
1-2 14% (10-18) 2.21 (1.25-3.91) b.001 1.25 (0.66-2.37) .315
N2 27% (22-32) 5.16 (3.11-8.56) 1.43 (0.71-2.88)
a Continuous data given as median (interquartile range); categorical data given as percentage (95% CI).
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prospective study that evaluated the occurrence of ARF in a
population of critically ill adults initially free of ARF [13]. In
that study, ARF was defined as the need for mechanical
respiratory support, including all methods of artificial ventila-
tion with or without the presence of an artificial airway, and no
minimum time on MV was required [13]. We believe our
chosen entry criteria are adequate to assess the real incidence of
ARF because patients ventilated for less than 24 hours usually
are not ventilated for reasons of ARF but for other causes (eg,
postoperative care and prolonged anesthesia). However, the
incidence of ARF in our study might be slightly under-
estimated, as our entry criterion excluded patients with ARF
who were treated with therapeutic options other than
endotracheal intubation plus MV (eg, intermittent or continu-
ous noninvasive ventilation) and patients with ARF dying
before the first 24 hours.
4.2. Risk factors
The development of ARF in our study population was
related to the patient's age, a longer time between hospital
and ICU admission, an ICU admission for unscheduled
surgery or medical reason, and greater severity of illness at
ICU admission, as evaluated by the APS score.In the only other epidemiologic study that reported risk
factors for ARF in a population initially free of this
syndrome, infection before and subsequent to ICU
admission, older age, and the presence of neurologic
failure on ICU admission were independently associated
with ARF development [13].
4.3. Mortality
In this study, ICU mortality in patients with ARF who
required MV for more than 24 hours was 48%. Our mortality
rate is higher than those quoted in other epidemiologic studies
with nonselected patients with ARF [1-3,13,14]. This may be
partially explained by our inclusion criteria (we have selected
a population with greater severity of illness, by excluding
patients with ICU stay ≤24 hours) and definition of ARF
(need for endotracheal intubation and invasiveMV for at least
24 hours).
Moreover, 86% of our patients with ARF were
admitted to the ICU with established ARF or requiring
MV within 48 hours after ICU admission highlights that
we may have problems with limited ICU beds or
inadequate perception of the severity in critically ill
patients at hospital admission, with patients being admitted
late in intensive care.
Table 4 Characteristics and outcomes of 984 patients with ARF admitted to an ICU during the study period, according to survival status a
Characteristic Patients with ARF
(n = 984)
Nonsurvivors of ARF
(n = 475)
Survivors of ARF
(n = 509)
P
Age, y 54 (38-70) 62 (42-72) 49 (34-64) b.001
Female 39% (36-43) 41% (37-46) 38% (34-42) .31
Time between hospital and
ICU admission, d
2 (0-7) 3 (1-9) 1 (0-5) b.001
Type of admission
Medical 50% (47-54) 64% (59-68) 38% (34-42) b.001
Scheduled surgical 27% (24-30) 16% (13-20) 36% (32-41)
Unscheduled surgical 23% (20-26) 20% (17-24) 26% (22-30)
Comorbidities
Cancer 21% (18-23) 17% (14-21) 24% (20-28) .01
Metastatic cancer 5% (4-7) 6% (4-9) 4% (2-6) .05
Hematologic cancer 4% (3-6) 7% (5-10) 1% (0.5-3) b.001
AIDS 4% (3-5) 6% (4-9) 2% (1-4) b.001
Trauma 14% (12-16) 8% (6-11) 19% (16-23) b.001
SAPS II score 37 (27-48) 44 (34-55) 30 (21-40) b.001
APS score 21 (13-31) 26 (17-35) 18 (12-25) b.001
LODS score 4 (2-6) 5 (3-7) 3 (2-5) b.001
Reason for MV initiation
Acute or chronic respiratory failure 4% (3-5) 3% (2-6) 4% (2-6) b.001
Coma 13% (11-15) 14% (11-18) 12% (9-15)
Neuromuscular disease 2% (1-3) 1% (0.3-2) 2% (1-4)
ARF due to
Trauma 6% (5-8) 3% (2-5) 9% (7-12)
ALI/ARDS 10% (9-12) 17% (14-21) 4% (2-6)
Postoperative 38% (35-41) 22% (19-26) 52% (48-56)
CHF 6% (4-8) 8% (6-10) 4% (3-6)
Pneumonia 8% (6-10) 10% (8-13) 5% (4-8)
Sepsis 7% (6-9) 11% (8-14) 3% (2-6)
Other 7% (6-9) 10% (8-13) 4% (3-7)
ARF developed during ICU stay
(late-onset ARF)
141 (14%) 108 (23%) 33 (6%) b.001
Duration of MV, d 5 (2-12) 7 (3-14) 3 (1-10) b.001
ICU LOS, d 9 (4-19) 10 (5-20) 8 (4-19) .18
Hospital LOS, d 21 (12-37) 17 (10-28) 25 (14-43) b.001
CHF indicates congestive heart failure.
c Continuous data given as median (interquartile range); categorical data given as percentage (95% CI).
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Although much of the current research on treatment of for
respiratory failure focuses on improving gas exchange, it is
controversial if the severity of the respiratory failure is
indicative of the severity of the disease process and of both
the risk for and cause of death [3,15], suggesting that other
risk factors may be related with the outcome in most ICU
patients with ARF.
We decided to study only variables that can be determined
before or at the start of MV, which could be used to predict
outcomes. Our findings are consistent with similar studies
indicated in brackets: older age [3,13,14], history of
hematologic malignancy or AIDS [3,13], ALI/ARDS as the
reason for the initiation of MV [14], and greater severity of
illness at ICU admission, as evaluated by the APS score. This
study expands on prior studies in at least 2 points: first, inrelation to the finding that ARF developed in the ICU, as
opposed to ARF already present at the time of admission, is a
prognostic factor of mortality, suggesting that there are
significant differences in the epidemiology and outcomes of
ARF depending on the time of ARF onset; second, the impact
of the time between hospital and ICU admission on the
mortality, which may reflect an inadequate care for this type
of patient before ICU admission, as was demonstrated in 50%
of ICU admissions in a Britannic study [16].
Our study has some limitations. First, it was performed in a
single medical center. Second, although this is a prospective
study, we were not able to measure all potential confounders.
If we had collected data on hospital admission or at the onset
of ARF in the ICU, we could find other variables influencing
the outcome. Despite these limitations, many of which are
inevitable in observational study, we believe that our central
conclusions remain valid.
Table 5 Mortality rate in ICU by selected characteristics of 984 patients with ARF—bivariate and multivariate analyses a
Characteristic ICU mortality,
% (95% CI)
Bivariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P
Age, y
b45 39% (34-44) 1.00 .312 1.00 .198
45-64 43% (37-48) 1.18 (0.86-1.61) b.001 1.31 (0.87-1.97) b.001
N64 63% (57-68) 2.64 (1.93-3.61) 3.29 (2.16-5.02)
Time between hospital and ICU admission, d
0 36% (30-42) 1.00 .003 1.00 .54
1-4 48% (43-53) 1.64 (1.19-2.27) b.001 1.13 (0.76-1.70) .021
N4 58% (53-64) 2.50 (1.78-3.49) 1.66 (1.08-2.56)
Type of admission
Scheduled surgical 29% (24-35) 1.00 .002 1.00 .054
Unscheduled surgical 42% (36-49) 1.79 (1.23-2.61) b.001 1.66 (0.99-2.76) .377
Medical 61% (57-66) 3.86 (2.80-5.33) 1.29 (0.73-2.29)
Comorbidities
Cancer 40% (34-48) 0.67 (0.49-0.92) .012 0.95 (0.59-1.54) .846
Metastatic cancer 62% (47-75) 1.80 (1.00-3.23) .049 1.75 (0.80-3.83) .164
Hematologic cancer 85% (71-94) 6.66 (2.78-15.99) b.001 3.99 (1.47-10.84) .007
AIDS 74% (58-87) 3.24 (1.56-6.72) .002 3.63 (1.54-8.52) .003
Trauma 29% (22-38) 0.40 (0.27-0.59) b.001 0.66 (0.33-1.31) .234
APS score
b16 32% (27-37) 1.00 b.001 1.00 .001
16-26 46% (40-51) 1.81 (1.32-2.49) b.001 2.13 (1.34-3.39) b.001
N26 69% (64-74) 4.87 (3.50-3.78) 5.37 (2.94-9.82)
LODS score
b3 31% (27-36) 1.00 b.001 1.00 .845
3-5 48% (42-53) 2.05 (1.48-2.83) b.001 0.96 (0.61-1.51) .850
N5 65% (60-70) 4.24 (3.05-5.90) 0.95 (0.53-1.69)
Reason for MV initiation
Acute or chronic respiratory failure 47% (30-65) 2.92 (1.19-7.19) .020 0.94 (0.28-3.15) .915
Coma 54% (44-62) 3.79 (1.90-7.57) b.001 1.03 (0.38-2.77) .950
Neuromuscular 25% (7-52) 1.10 (0.30-3.94) .889 0.69 (0.14-3.26) .637
ARF due to
Trauma 23% (13-36) 1.00 b.001 1.00 .001
ALI/ARDS 81% (72-88) 14.18 (6.51-30.9) .377 4.94 (1.90-12.84) .528
Postoperative 29% (24-34) 1.33 (0.70-2.53) b.001 0.75 (0.31-1.83) .629
CHF 63% (49-76) 5.63 (2.52-12.60) b.001 1.31 (0.44-3.94) .442
Pneumonia 64% (52-74) 5.72 (2.67-12.26) b.001 1.52 (0.53-4.37) .186
Sepsis 75% (64-85) 10.05 (4.47-22.62) b.001 2.09 (0.70-6.22) .167
Other 68% (56-79) 7.02 (3.21-15.37) b.001 2.13 (0.73-6.23) .001
ARF developed during ICU stay (late-onset ARF) 77% 1.71 (1.45-2.0) b.001 5.09 (3.07-8.46) b.001
a Continuous data given as median (interquartile range); categorical data given as percentage (95% CI).
330.e7The epidemiology of acute respiratory failureIn conclusion, patients with ARF form a large percentage
of all ICU admissions. Because patients with ARF require,
besides respiratory support, a complex, well-organized, and
technically sophisticated level of care, several institutional
and health care system approaches may improve care of these
patients, including the implementation of a range of best
practices [17] and protocols for identifying high-risk MV
patients to improve the respiratory assistance and, if
necessary, provide an earlier ICU admission for therapeutic
measures such as respiratory therapy and use of noninvasive
MV [18]. In some instances, the regionalization of care in the
ICU for selected high-risk MV patients could be useful [19].Acknowledgments
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